Systematic identification of novel cancer genes through analysis of deep shRNA perturbation screens

Author:

Montazeri Hesam12,Coto-Llerena Mairene23,Bianco Gaia23,Zangene Ehsan1,Taha-Mehlitz Stephanie3,Paradiso Viola2,Srivatsa Sumana45,de Weck Antoine6,Roma Guglielmo6,Lanzafame Manuela2ORCID,Bolli Martin7,Beerenwinkel Niko45ORCID,von Flüe Markus7,Terracciano Luigi M89,Piscuoglio Salvatore23,Ng Charlotte K Y21011ORCID

Affiliation:

1. Department of Bioinformatics, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran

2. Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland

3. Visceral Surgery and Precision Medicine Research laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland

4. Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland

5. SIB Swiss Institute of Bioinformatics, Basel, Switzerland

6. Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland

7. Clarunis, Department of Visceral Surgery, University Centre for Gastrointestinal and Liver Diseases, St. Clara Hospital and University Hospital Basel, Switzerland

8. Department of Pathology, Humanitas Clinical and Research Center, IRCCS, Milan, Italy

9. Department of Biomedical Sciences, Humanitas University, Milan, Italy

10. Department for BioMedical Research, University of Bern, Bern, Switzerland

11. SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland

Abstract

Abstract Systematic perturbation screens provide comprehensive resources for the elucidation of cancer driver genes. The perturbation of many genes in relatively few cell lines in such functional screens necessitates the development of specialized computational tools with sufficient statistical power. Here we developed APSiC (Analysis of Perturbation Screens for identifying novel Cancer genes) to identify genetic drivers and effectors in perturbation screens even with few samples. Applying APSiC to the shRNA screen Project DRIVE, APSiC identified well-known and novel putative mutational and amplified cancer genes across all cancer types and in specific cancer types. Additionally, APSiC discovered tumor-promoting and tumor-suppressive effectors, respectively, for individual cancer types, including genes involved in cell cycle control, Wnt/β-catenin and hippo signalling pathways. We functionally demonstrated that LRRC4B, a putative novel tumor-suppressive effector, suppresses proliferation by delaying cell cycle and modulates apoptosis in breast cancer. We demonstrate APSiC is a robust statistical framework for discovery of novel cancer genes through analysis of large-scale perturbation screens. The analysis of DRIVE using APSiC is provided as a web portal and represents a valuable resource for the discovery of novel cancer genes.

Funder

Swiss Cancer League

Swiss National Science Foundation

AIRC

European Research Council

Theron Foundation, Vaduz

Publisher

Oxford University Press (OUP)

Subject

Genetics

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3